Tag: chemotherapy

1. Progression-free survival was extended by the use capecitabine as compared to active monitoring, but at the expense of increased toxicity. There was no difference in overall survival between treatment arms. 2. Quality of life scores were similar between the two treatment arms. Evidence Rating Level: 1 (Excellent) Study Rundown: Current standards...

Click to read the study in JAMA Oncology.

Click to read the study in JAMA Oncology. 

1. Age group was not significantly associated with variations in treatment for extremity soft-tissue sarcoma decisions, except for the use of chemotherapy and radiation therapy, where younger patients were more likely to receive chemotherapy and less likely to receive radiation therapy. 2. Additional studies are warranted to correlate the clinical...

1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone. 2. Severe adverse events occurred more frequently in the nivolumab group and more patients withdrew from treatment due to these events. Evidence Rating Level: 1 (Excellent) Study Rundown: The 5-year survival rate of patients...

1. Although combining pembrolizumab to chemoradiotherapy as part of total neoadjuvant therapy after FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) treatment was safe overall, the difference in neoadjuvant rectal score does not support further study of this novel combination for the treatment of locally advanced rectal cancer. 2. These results and the...

1. Chemotherapy was associated with an increased risk of major congenital malformations in the initial 12 weeks of pregnancy. 2. These risks and the prevalence of incidental pregnancies concurrent to chemotherapeutic treatments emphasizes the importance of prenatal and perinatal counselling for women of child-bearing age with cancer. Evidence Rating Level: 2...

Click to read the study in The Lancet Oncology.

1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to single-agent chemotherapy treatment. 2. Sacituzumab govitecan was associated with more frequent events of myelosuppression and diarrhea compared to chemotherapy treatment. Evidence Rating Level: 1 (Excellent) Study Rundown: Breast cancer patients with triple-negative status...